BridgeMD
Concomitant HPV vaccination and HPV screening for rapid elimination of HPV infection and cervical cancer in Sweden
EU CTIS ID: 2024-518857-41-00
What this study is testing
The study aims to evaluate whether organised, concomitant HPV vaccination and HPV screening offered by the Swedish cervical screening program to all resident women aged 23-25 will result in a more rapid elimination of HPV infection in Sweden. This objective will be examined at the population level.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Eligible women will include resident women within the age range of 23- 25 due for invitation to organised cervical cancer screening who consent to participate in the study.
You likely can't join if
- Known history of severe allergic reaction or hypersensitivty to any of the components of the HPV vaccine. For GARDASIL 9: Amorphous aluminium hydroxyphosphate sulphate adjuvant, Sodium chloride, L-histidine, Polysorbate 80 or Sodium borate.
- Known history of immune-related disorders.
- Current acute severe febrile illness, except for minor infections such as a cold, mild upper respiratory infection or low-grade fever.
- Administration of immunoglobulin or blood-derived products within 6 months prior to scheduled HPV vaccine first dose.
- Current pregnancy (reported).
- Hysterectomized women.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.